SSc development
SSc onset
complications of SSc
MIRASYS team
Early detection of SSc
diagnostic potential of miRNAs
need
stage diagnosis
miRNA panel
specific miRNAs
diagnostic properties
diagnostic assay
early diagnosis of Systemic Sclerosis Systemic sclerosis
strong IP strategy
breakthrough diagnostic potential
stage clinical symptoms
strong business plan
MIRASYS ERC PoC Grant
potent miRNAs
IP landscape
IP position
strong support
findings
clinical progression
late clinical manifestations
business professionals
business models
miRNA expression level boundaries
proprietary ERC research specific microRNA
combination of late
disease monitoring
strategic investors
in-depth market research
commercial feasibility of setting
life-long burden of disease
life-threatening autoimmune connective tissue disorder of unknown cause
prognostic
similar approaches
prior art
fibrosis
experienced science
dedicated spin-off company
steps
profiles
actionable biomarkers
skin
internal organs
technology
Freedom
commercialisation
subjects
years
patients
Current diagnostics
results